使用仿制药进行肝细胞癌化学预防

StephenW

使用仿制药进行肝细胞癌化学预防
Fahmida Rasha 1 , Subhojit Paul 1 , Tracey G Simon 2 , Yujin Hoshida 1
隶属关系
隶属关系

    1
    内科，德克萨斯大学西南医学中心，达拉斯，美国。
    2
    美国波士顿马萨诸塞州总医院胃肠病学、临床和转化流行病学部门。

    PMID：36104114 DOI：10.1055/a-1942-6693

抽象的

肝癌，主要是肝细胞癌 (HCC)，仍然是全世界癌症相关死亡的主要原因。随着全球肥胖症的流行，主要的 HCC 病因已从病毒性肝病动态转变为代谢性肝病。这种变化使HCC的预防变得困难，因为越来越难以捉摸的高危人群作为预防干预的合理目标。除了不断努力减少肥胖和代谢紊乱外，对已经患有代谢性肝病的患者进行化学预防将对不良的 HCC 预后产生重大影响。新的抗病毒药物已大大降低了乙型和丙型肝炎相关 HCC 的发病率，但即使在成功进行病毒治疗后，HCC 风险仍可能持续十年以上，这凸显了在这些患者中也需要采取 HCC 预防措施。实验和回顾性研究表明，亲脂性他汀类药物和阿司匹林等仿制药具有良好的安全性特征，可用于 HCC 化学预防，尽管预期疗效可能不大。在这篇综述中，我们概述了在当代 HCC 病因下 HCC 化学预防背景下仿制药的最新临床和转化研究。我们还讨论了克服药物临床测试挑战以促进其临床转化的新兴方法。

蒂姆。版权所有。
利益冲突声明

T.G.S.担任 Aetion 的顾问并获得安进的资助。 Y.H.担任 Helio Genomics 和 Espervita Therapeutics 的顾问委员会成员，以及 Alentis Therapeutics 和 Espervita Therapeutics 的股东。

StephenW

Hepatocellular carcinoma chemoprevention with generic agents
Fahmida Rasha  1 , Subhojit Paul  1 , Tracey G Simon  2 , Yujin Hoshida  1
Affiliations
Affiliations

    1
    Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, United States.
    2
    Division of Gastroenterology, Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, United States.

    PMID: 36104114 DOI: 10.1055/a-1942-6693

Abstract

Liver cancer, mainly hepatocellular carcinoma (HCC), remains a major cause of cancer-related death worldwide. With the global epidemic of obesity, the major HCC etiologies have been dynamically shifting from viral to metabolic liver diseases. This change has made HCC prevention difficult with increasingly elusive at-risk populations as rational target for preventive interventions. Besides ongoing efforts to reduce obesity and metabolic disorders, chemoprevention in patients who already have metabolic liver diseases will have a significant impact on the poor HCC prognosis. Hepatitis B- and C-related HCC incidences have been substantially reduced by the new anti-virals, but HCC risk can persist over a decade even after successful viral treatment, highlighting the need for HCC-preventive measures also in these patients. Experimental and retrospective studies have suggested potential utility of generic agents such as lipophilic statins and aspirin for HCC chemoprevention given their well characterized safety profile, although anticipated efficacy may be modest. In this review, we overview recent clinical and translational studies of generic agents in the context of HCC chemoprevention under the contemporary HCC etiologies. We also discuss newly emerging approaches to overcome the challenges in clinical testing of the agents to facilitate their clinical translation.

Thieme. All rights reserved.
Conflict of interest statement

T.G.S. serves as a consultant for Aetion and receives grant from Amgen. Y.H. serves as an advisory board member for Helio Genomics and Espervita Therapeutics, and shareholder for Alentis Therapeutics and Espervita Therapeutics.